Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells

Cytokine

Volumn 17, Issue 5, 2002, Pages 234-242

  Duan, Z ^a   Lamendola, D E ^a   Penson, R T ^a   Kronish, K M ^a   Seiden, M V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug resistance; IL 6; Ovarian cancer; Paclitaxel

Indexed keywords

CASPASE 3; DOXORUBICIN; GLYCOPROTEIN P; INTERLEUKIN 6; INTERLEUKIN 8; LUNG RESISTANCE PROTEIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; RHODAMINE 123; TOPOTECAN; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASPASE; COMPLEMENTARY DNA; RNA; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY TEST; DRUG SENSITIVITY; ENZYME ACTIVATION; EXPRESSION VECTOR; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; WESTERN BLOTTING; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; DOSE RESPONSE; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; METABOLISM; OSTEOSARCOMA; TIME;

VECTORS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, NORTHERN; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL DIVISION; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MITOXANTRONE; OSTEOSARCOMA; P-GLYCOPROTEIN; PACLITAXEL; PHENOTYPE; RNA; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TOPOTECAN; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035986837     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2001.1008     Document Type: Article

References (36)

1. Paclitaxel has moderate activity in squamous cervix cancer: A Gynecologic Oncology Group Study
2. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel
3. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes
4. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: Analysis of IL-6, IL-8 and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype
5. Quantitation of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in the effusions of ovarian epithelial neoplasms
6. Cytokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel
7. Interleukin-6 in biology and medicine
8. Autocrine generation and requirement of BSF/IL-6 for human multiple myelomas
9. AIDS Kaposi sarcoma-derived cells produce and respond to IL-6
10. A possible autocrine role for interleukin-6 in two lymphoma cell lines
11. Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma
12. Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis
13. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma
14. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligo-nucleotides
15. Doxorubicin and daunomycin induce programmed cell death (apoptosis) in tumor cells
16. Control of programmed cell death in normal and leukemic cells: New implications for therapy
17. Wild-type p53 induced apoptosis of myeloid leukemic cells that is inhibited by interleukin-6
18. Interleukin-8 and MCAF: Novel leukocyte recruitment and activity cytokines
19. Interleukin-8 as a macrophage-derived mediator of angiogenesis
20. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/IL-8
21. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer
22. Evaluation of a tetrazolium-based semiautomated colormetric assay: Assessment of chemosensitivity testing
23. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug Screen
24. Acquisition of Taxol resistance via P-glycoprotein and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells
25. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer
26. Prognostic significance of interleukin-6 serum levels in patients with ovarian cancer
27. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody of anti-interleukin-6 receptor monoclonal antibody
28. A family of drug transporters: The multidrug resistance-associated proteins
29. The drug resistance-related protein LRP is the human major vault protein
30. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency
31. Alkylating agent resistance; in vitro studies with human cell lines
32. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators
33. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
34. Expression of the c-H-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin
35. Bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs
36. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu